In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on Achieve Life Sciences (ACHV – Research Report), with a price target of $35.00. The company’s shares opened today at $7.80.
Higgins covers the Healthcare sector, focusing on stocks such as Achieve Life Sciences, SCYNEXIS, and Palatin Technologies. According to TipRanks, Higgins has an average return of 2.4% and a 32.39% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Achieve Life Sciences with a $24.67 average price target, which is a 216.28% upside from current levels. In a report released on May 10, Lake Street also maintained a Buy rating on the stock with a $22.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $10.30 and a one-year low of $2.00. Currently, Achieve Life Sciences has an average volume of 137.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products, cytisine, is a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.
Read More on ACHV:
- Achieve Life Sciences Reports Statistically Significant Smoking Cessation Benefit for Cytisinicline in Second, Confirmatory Phase 3 Clinical Trial
- Achieve Life Sciences Announces Refinancing of Outstanding Loan with Silicon Valley Bank
- ACHV Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Achieve Life Sciences to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 9, 2023
- Achieve Life Sciences announces Phase 2 ORCA-V1 trial results
